Ariceum Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 11

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $52M

  • Investors
  • 8

Ariceum General Information

Description

Developer of targeted radiopharmaceuticals designed to visualize, diagnose, and treat aggressive and hard-to-cure cancers. The company's radiopharmaceuticals combine tumor-targeting molecules with therapeutic or diagnostic radioisotopes to selectively deliver radiation to cancer cells, with programs targeting somatostatin receptor 2 and PARP-expressing tumors, enabling medical professionals to develop better-targeted drugs to eradicate cancer more efficiently with fewer side effects.

Contact Information

Formerly Known As
Platin 2100, SatoSea Oncology
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Robert-Rössle-Straße 10
  • Building 79
  • 13125 Berlin
  • Germany
+49 030
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Corporate Office
  • Robert-Rössle-Straße 10
  • Building 79
  • 13125 Berlin
  • Germany
+49 030

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ariceum Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 18-Apr-2023 $52M Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view Ariceum’s complete valuation and funding history, request access »

Ariceum Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of targeted radiopharmaceuticals designed to visualize, diagnose, and treat aggressive and hard-to-cure cancer
Drug Discovery
Berlin, Germany
11 As of 2026

Cerdanyola, Spain
 

Pasadena, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ariceum Competitors (52)

One of Ariceum’s 52 competitors is Ability Pharma, a Private Equity-Backed company based in Cerdanyola, Spain.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ability Pharma Private Equity-Backed Cerdanyola, Spain
Meditope Biosciences Formerly VC-backed Pasadena, CA
Navidea Biopharmaceuticals Corporate Backed or Acquired Columbus, OH
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Linnaeus Therapeutics Venture Capital-Backed Haddonfield, NJ
You’re viewing 5 of 52 competitors. Get the full list »

Ariceum Patents

Ariceum Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-12343409-B1 Radiopharmaceutical composition and methods Active 05-Jun-2024
US-20250375541-A1 Radiopharmaceutical composition and methods Inactive 05-Jun-2024
WO-2025255396-A1 Radiopharmaceutical composition and methods Pending 05-Jun-2024
WO-2025255398-A1 Radiopharmaceutical composition and methods Pending 05-Jun-2024
AU-2023389058-A1 Alpha emitter labelled somatostatin receptor antagonists Pending 06-Dec-2022 A61K51/088
To view Ariceum’s complete patent history, request access »

Ariceum Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ariceum Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Andera Partners PE/Buyout Minority
Earlybird Venture Capital Venture Capital Minority
EQT Life Sciences Venture Capital Minority
HealthCap Venture Capital Minority
Ipsen Corporation Minority
You’re viewing 5 of 8 investors. Get the full list »

Ariceum Investments & Acquisitions (2)

Ariceum’s most recent deal was a Merger/Acquisition with Theragnostics for . The deal was made on 01-Jun-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Theragnostics 01-Jun-2023 Merger/Acquisition Diagnostic Equipment
Ipsen (Rights to Satoreotide) 22-Oct-2021 Corporate Asset Purchase Buildings and Property
To view Ariceum’s complete investments and acquisitions history, request access »

Ariceum Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Theragnostics London, United Kingdom 2013

Ariceum FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process